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Assessing response to interferon-b in
a multicenter dataset of patients with MS
ABSTRACT
Objective: To provide new insights into the role of markers of response to interferon-b therapy in
multiple sclerosis (MS) in a multicenter setting, focusing on the relevance of MRI lesions in com-
bination with clinical variables.
Methods: A large multicenter clinical dataset was collected within the Magnetic Resonance
Imaging in MS (MAGNIMS) network. This included a large cohort of patients with relapsing-
remitting MS on interferon-b treatment, MRI and clinical assessments during the first year of
treatment, and clinical follow-up of at least 2 additional years. Heterogeneity among centers was
assessed before pooling the data. The association of 1-year MRI or clinical relapses with the risk
of treatment failure (defined as Expanded Disability Status Scale [EDSS] worsening or treatment
switch for inefficacy) and of EDSS worsening alone was evaluated using multivariate Cox
models.
Results: A pooled dataset of 1,280 patients with relapsing-remitting MS from 9 MAGNIMS cen-
ters was analyzed. The risk of failure had a relevant increase with 1 relapse (hazard ratio [HR]
1.84, 95% confidence interval [CI] 1.39–2.44, p , 0.001) and $3 new T2 lesions (HR 1.55,
95%CI 0.92–2.60, p5 0.09). In patients without relapses and less than 3 new T2 lesions, the 3-
year risk of failure and EDSS worsening were 17% and 15%; in patients with 1 relapse or $3
new T2 lesions, the risks were 27% and 22%; in patients with both conditions or more than 1
relapse, the risks were 48% (p , 0.001) and 29% (p , 0.001).
Conclusions: Substantial MRI activity, particularly if in combination with clinical relapses, during
the first year of treatment with interferon-b indicates significant risk of treatment failure and
EDSS worsening in the short term. Neurology® 2016;87:134–140
GLOSSARY
CI 5 confidence interval; EDSS 5 Expanded Disability Status Scale; HR 5 hazard ratio; IFN 5 interferon; MAGNIMS 5
Magnetic Resonance Imaging in MS; MS 5 multiple sclerosis; NPV 5 negative predictive value; PPV 5 positive predictive
value; RRMS 5 relapsing-remitting multiple sclerosis.
Several new and highly active drugs have recently been approved for the treatment of multiple
sclerosis (MS), necessitating prompt and informed treatment decisions in patients with suboptimal
response to potentially less efficacious treatments. This is difficult due to the inherent uncertainties
in defining nonresponse to therapy in a chronic disease such as MS,1 and complicated by the lack
of a standardized definition of the clinical outcomes used to assess worsening of the disease.2
Many studies have evaluated the role of clinical and MRI markers to define nonresponders to
interferons (IFNs), reporting conflicting results.3–11 On this basis, a recent meta-analysis aiming
at establishing the relevance of MRI markers in predicting a higher risk of disability progression
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failed to combine most of the published stud-
ies in a quantitative summary estimate, due to
the large heterogeneity in both measured
markers and outcome assessments.12 This het-
erogeneity precludes a valuable comparison of
the different markers and scores of response
across different studies.
To provide new insights into the role of
markers of response to IFN-b therapy, we
analyzed a large multicenter dataset collected
within the Magnetic Resonance Imaging
in MS (MAGNIMS) network and including
a cohort of patients with relapsing-remitting
MS (RRMS) on treatment with IFN-b. The
aim was to explore whether in patients treated
with IFN-b even minimal increases in the
number of MRI lesions could be highly pre-
dictive of a treatment failure or if a substantial
number of new MRI lesions, eventually in
combination with clinical relapses, are neces-
sary to best predict IFN-b treatment failure.
METHODS Study population. The present analysis was run
on an integrated dataset including data from 1,890 patients with
RRMS treated with IFN-b for at least 1 year (table 1) from 10
MAGNIMS centers. We included retrospectively patients with
RRMS treated with any approved preparation of IFN-b as their
first therapy, with assessments of Expanded Disability Status
Scale (EDSS) score, number of relapses and number of T2 lesions
at therapy initiation and after 1 year, and at least yearly clinical
assessments, including EDSS score and number of relapses, for
a minimum of 2 additional years (3 years from treatment initia-
tion). The allowed time windows for 1-year MRI and clinical
examination was 2 months. Dates of treatment switch and
reasons for switching, as well as the new drug in case of switch
and the last available EDSS assessment and last follow up date,
were collected.
Outcome measures. The definition of treatment failure was
based on 2 failure events, whichever occurred first:
1. A confirmed EDSS worsening (according to Rio et al.1), here
defined and re-estimated for all the included datasets, as $1
point EDSS increase (0.5 point if baseline EDSS $5.5 and
1.5 points if baseline EDSS5 0) confirmed at the subsequent
visit (6 [or 12] months apart [if the 6-month visit is missing]).
EDSS at month 12 was used as the starting point to evaluate
progression. Since EDSS progression is the final outcome
indicating nonresponse to treatment, it was not included in
the set of markers of response. Therefore, patients with an
EDSS progression during the first year of therapy, if con-
firmed in subsequent visits, were considered progressed pa-
tients at year 1.
2. A switch to other therapies for lack of efficacy. Two fields of
the merged dataset were used for this definition: the reason for
switching (inefficacy, tolerability, or others) must be ineffi-
cacy; the new drug used should be any second-line therapy
according to the European Medicine Agencies13 (http://www.
ema.europa.eu/ema/) regulation. Switches among different
IFN-bs were not considered as treatment changes if done
within a time frame of 1 or 2 months. Otherwise the time
to failure was censored at the time of switching.
We also ran the analysis considering all the switches as cen-
sored observations and using the time to EDSS worsening as pre-
viously defined as the final outcome.
Standard protocol approvals, registrations, and patient
consents. The original raw data collections were approved by the
local ethics committees at all centers and written informed con-
sent was obtained from all study patients.
Statistical analyses. Heterogeneity among the MAGNIMS
centers was evaluated by grouping centers that enrolled a number
of patients ,10% of the total (,200 patients).
Heterogeneity in baseline characteristics was evaluated by an
analysis of variance model or a x2 test, depending on the nature of
the evaluated variable. Heterogeneity in 1-year assessments (num-
ber of new T2 lesions and number of relapses) was assessed by
a negative binomial model. Heterogeneity in time to treatment
failure and time to EDSS worsening was assessed by Kaplan-
Meier curves and the log-rank test.
Survival analysis methods were used to account for the differ-
ent follow-up lengths. Before pooling all the datasets, an assess-
ment of heterogeneity regarding the effect of markers assessed
at 1 year after treatment start on time to failure was carried out
by an interaction test in a multivariate Cox model, with the time
to failure from year 1 to the last follow-up as the dependent vari-
able. A significant p value for the interaction test means that there
is a relevant heterogeneity among centers in the effect of 1-year
markers on time to failure.
In the final model, clinical relapses were entered as a 3-level
variable (0, 1, 2, or more) and new T2 lesions as a 7-level variable
(0, 1, 2, 3, 4, 5, 6, or more) using a stepwise procedure to check
whether both markers are included in the final model and which
marker was entered first. Their relative contribution to the risk of
failure was evaluated using the relative change in log-likelihood
induced by each factor. The best cutoff value for the number
of new T2 lesions counted over the first year, leading to an
increase in the risk of failure during follow-up, was assessed as
the number of lesions causing a relevant change in the hazard
ratio (HR) as compared to the reference level (0 new T2 lesions).
The combination of 1-year markers obtained was related to
the time of EDSS worsening using a Cox model.
Table 1 Patients included in the analysis and
participating centers
Centers Patients included, n (%)
Rome 610 (32.3)
Milan 568 (30.1)
Barcelona 233 (12.3)
Bari 120 (6.3)
Cagliari 106 (5.6)
Siena 91 (4.9)
Verona 88 (4.7)
Graz 32 (1.7)
Napoli 27 (1.4)
Basel 14 (0.7)
Total 1,890 (100)
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Kaplan-Meier survival curves were used to display the results.
RESULTS Dataset description. The centers included
in the analysis, along with the number of patients pro-
vided, are reported in table 1. Baseline characteristics
are reported in table 2, with centers grouped as Rome
(n 5 610), Milan (n 5 568), Barcelona (n 5 233),
and other MAGNIMS centers (n 5 479).
Some datasets have been already used in previous
publications: the Barcelona dataset and the Milan da-
taset were both analyzed to validate the Modified Rio
Score,8,9 while the Rome dataset was an updated ver-
sion of a dataset used to assess the effect of MRI
lesions on progression.5,6
EDSS was assessed by each center at 6-month
intervals.
As expected in a nonrandomized, clinically based
population, there were some heterogeneities regard-
ing demographic and clinical characteristics across
centers as well as in the number of lesions and relapses
detected during the first year of therapy (table 2).
This heterogeneity can be accounted for in the main
analysis, by adjusting for baseline factors. The pro-
portion of patients with a treatment failure at year 3
after the first year of treatment was homogenous
across centers (appendix e-1 and figure e-1 on the
Neurology® Web site at Neurology.org): the total
number of events was 413 (3-year risk of failure
23% [SE 1%]). Also, the proportion of patients with
an EDSS worsening at year 3 after the first year of
treatment was homogenous across centers (appendix
e-1 and figure e-2): the total number of events was
321 (3-year risk of failure 18% [SE 1%]).
Heterogeneity assessment. To assess whether the data
can be pooled to find the best predictors of treatment
failure in a merged dataset, homogeneity of effects
was evaluated first. The effect of relapses (adjusted
for new T2 lesions) on treatment failure was not sig-
nificantly heterogeneous across centers (p for interac-
tion 5 0.44); the effect of new T2 lesions was highly
heterogeneous among centers (p for interaction
,0.001). This heterogeneity did not change adjust-
ing the Cox model for all baseline variables (age, sex,
baseline EDSS, disease duration). Also, the results
remained unchanged when considering the switch
for inefficacy as a censored observation rather than
an event. The heterogeneity only disappeared when
the Rome center was excluded from the analyses. The
reasons for this heterogeneity are further explored and
the full analysis is reported in appendix e-1, table e-1,
and figures e-3–e-5. On the basis of the results of the
test for heterogeneity, the Rome center was not
included in the pooled analysis.
Combining the predictors in a score. In the merged
MAGNIMS dataset (n 5 1,280), we estimated the
average effect of the number of new T2 MRI lesions
and relapses during the first year of treatment on risk
of failure at follow-up. For completeness, an analysis
on how, in the Rome dataset, the presence of relapse
or MRI lesions in 1 year of IFN-b can predict risk of
failure during follow-up is reported in appendix e-1.
Table 2 Characteristics of the included patients at treatment start (baseline) and after the first year of
treatment
Center
Age, y, median
(range)
EDSS, median
(range)
Disease duration,a
y, median (range)
Relapses previous
year, median (range)
Baseline characteristics (treatment start)
Rome 31 (10–56) 1.5 (0–4) 2.3 (0.0–25.8) 1 (0–4)
Milan 33 (13–64) 1.5 (0–5.5) 3.4 (0.1–33.8) 2 (0–6)
Barcelona 33 (17–69) 2 (0–6) 3.0 (1.0–47.0) 2 (0–6)
Other MAGNIMS 34 (13–59) 1.5 (0–5.5) 2.1 (0–25.6) 1 (0–5)
p Valuea ,0.001 ,0.001 ,0.001 ,0.001
Center
No. of 1-y new
T2 lesions,
mean (range)
No. of 1-y relapses,
mean (range)
Patients with new
T2 lesions, %
Patients with
relapses, %
Characteristics after 1 y from
treatment start
Rome 1.1 (0–13) 0.3 (0–3) 45 25
Milan 0.7 (0–20) 0.46 (0–5) 30 32
Barcelona 1.2 (0–20) 0.3 (0–4) 30 23
Other MAGNIMS 0.7 (0–15) 0.3 (0–5) 28 24
p Valuea ,0.001 ,0.001 ,0.001 ,0.001
Abbreviations: EDSS 5 Expanded Disability Status Scale; MAGNIMS 5 Magnetic Resonance Imaging in MS.
ap Value refers to the heterogeneity test across centers.
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To provide quantitative risk estimation according
to 1-year clinical and MRI events, we evaluated
a global score, based on the optimized cutoffs of
new T2 lesions and relapses found in the merged
MAGNIMS dataset. In table 3 the HR for relapses
(0, 1, 21) and new T2 lesions (0, 1, 2, 3, 4, 5, 61)
over the first year of therapy are reported. The Cox
model shows that the risk of failure significantly
increases with 1 relapse (HR 1.84, 95% confidence
interval [CI] 1.39–2.44, p, 0.001) and with at least
3 new T2MRI lesions (HR 1.55, 95%CI 0.92–2.60,
p5 0.09). Relapses were the factor first entered in the
model in a stepwise procedure, accounting for 66% of
the final log-likelihood change, while new T2 lesions
accounted for additional 34% of the total log-
likelihood change.
According to these results, risk levels were grouped
in 3 classes: group 05 those without relapses and less
than 3 new T2 lesions; group 1 5 those with 1
relapse or $3 new T2 lesions; group 2 5 those with
1 relapse and $3 new T2 lesions or $2 relapses.
In figure 1, the 3-year risk of treatment failure
after 1 year of therapy is reported for patients of the
MAGNIMS dataset according to groups described
above: patients in group 0 (n 5 849, 66%) showed
a minimal probability of treatment failure after 3
years (17%); patients in group 1 (n 5 301, 24%,
HR 1.85, p , 0.001) had an intermediate risk of
treatment failure over 3 years (27%); patients in
group 2 (n5 130, 10%) had a high risk of treatment
failure over 3 years (48%, HR 3.81, p , 0.001).
Score 0 vs scores 1 or 2 had a positive predictive
value (PPV) of 34% and a negative predictive value
(NPV) of 83%, a sensitivity of 49%, a specificity of
70%, and a global accuracy of 65%.
The same trend holds true when considering
EDSS worsening as the outcome (figure 2): patients
in group 0 showed a probability of EDSS worsening
after 3 years of 15%, patients in group 1 had an
intermediate risk of treatment failure over 3 years
(22%, HR 1.52, p 5 0.008), while those in group
3 have the highest risk of EDSS worsening (29%, HR
2.09, p , 0.001).
Score 0 vs scores 1 or 2 had a PPV of 26% and an
NPV of 86%, a sensitivity of 50%, a specificity of
70%, and a global accuracy of 66%.
DISCUSSION The possibility of setting simple rules,
based on early detection of MRI lesions and relapses,
for defining patients who are not responding to IFN-b
therapy has been largely debated.1–10 The discussion
focuses on 2 main issues: Shall we tolerate a degree
of disease activity before defining a patient as non-
responder to a therapy? In this case, how can we
define a cutoff indicating the level of disease activity
to be tolerated? Likely, the main limitation for
a proper answer to these questions is the lack of
consistent evidence on the clinical relevance of the
most used outcomes of disease progression, particu-
larly cerebral MRI.
While there is enough consensus on the presence
of clinical signs as predictors of nonresponse,1,14,15
the value of MRI focal lesions in defining response
to therapy is less clear. In this context, previous
Figure 1 Treatment failure–free survival
Treatment failure–free survival over 3 years in the merged Magnetic Resonance Imaging in
MS dataset (1,280 patients) following the first year of therapy, according to the different
combinations of new T2 lesions and relapses during the first year of therapy grouped in a 3-
level score.
Table 3 Multivariate Cox model on the merged MAGNIMS dataset for risk of
3-year treatment failure on 1-year variables (excluding Rome center)
(n 5 1,280)
Variables HR (95% CI) p Value
New T2 lesions 5 0 Ref
New T2 lesions 5 1 0.93 (0.62–1.4) 0.76
New T2 lesions 5 2 1.13 (0.73–1.76) 0.58
New T2 lesions 5 3 1.55 (0.92–2.60) 0.09
New T2 lesions 5 4 2.36 (1.35–4.16) ,0.001
New T2 lesions 5 5 1.87 (0.81–4.37) 0.14
New T2 lesions 5 61 2.57 (1.53–4.33) ,0.001
Relapse 5 0 Ref
Relapse 5 1 1.84 (1.39–2.44) ,0.001
Relapse 5 21 3.03 (2.06–4.45) ,0.001
Abbreviations: CI 5 confidence interval; HR 5 hazard ratio; MAGNIMS 5 Magnetic Reso-
nance Imaging in MS.
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work5,6 has shown that 1 new MRI lesion in the first
year of therapy, even without any clinical relapse, is
enough to highly increase the risk of disability pro-
gression thereafter (2–3 years). In contrast, other
work based both on experts’ consensus14,15 and on
evidence coming from analysis of clinical practice
and clinical trial data1–5,8 has shown that a substantial
increase in MRI lesions over 1 year treatment, better
with concomitant clinical evidence of disease activity,
is required before expecting a consistent increase in
the risk of short-term disability progression.
In the present study, we ran a new analysis on
a large, multicenter dataset collected within the
MAGNIMS network with the final outcome (dis-
ability progression) that was uniformly defined.
We first realized that it was impossible to pool all
the collected data because of an evident heterogene-
ity in the correlation between MRI lesions and the
risk of disability progression, mainly due to the
Rome center. This observation was not surprising,
since the dominant role of MRI lesions was previ-
ously published on the same dataset5,6 that was just
updated for the present analysis. The basic principle
for pooling data is the homogeneity of the results to
be pooled. Thus, in presence of high heterogeneity,
it is better to try to explain it, rather than obtaining
an average estimate. We therefore performed addi-
tional analyses on the Rome dataset aiming at
investigating the reasons for the heterogeneity,
which we reposted in appendix e-1.
On the pooled MAGNIMS dataset, the presence
of relapses during the first year of IFN-b therapy
was the main predictor of the risk of disability pro-
gression over the subsequent 3 years. Moreover, the
presence of MRI lesions increased the ability to pre-
dict disability progression and the cutoff value indi-
cating a substantial risk increase was the presence of at
least 3 new T2 lesions. Whereas these results seem to
be robust in predicting short-term risk of disability,
the scenario could be very different for the long-term
risk.11,16 Additional studies facing this important aim
are needed.
It must be stressed here that it is generally difficult
to define a universally valid cutoff of MRI lesions.
The sensitivity in detecting and counting new lesions
depends on many MRI variables,17,18 which include
the acquisition protocol, the frequency of scanning,
the time from basal MRI to treatment initiation,
and the rater assessing the lesions.19,20 While in clin-
ical trials there is the attempt to homogenize scanner
field strengths, acquisition protocols, frequency of
scanning, and even the lesion assessments through
a central reading of MRI scans, this is not done in
clinical practice and may have an effect on the lesions
counted on different MRI sequences, in different pe-
riods, and by different raters. In this respect, however,
the results reported here are likely to be closer to the
clinical practice scenario. In addition, usually cutoffs
of MRI lesion numbers do not consider the clinical
relevance of the anatomic location of lesion occur-
rence, as we also did not in the present study. Finally,
when assessing therapy response, the occurrence of
new lesions should always be interpreted in relation
to patient’s MRI activity in the recent past and to the
time elapsed from the reference scan and the pharma-
codynamics of the therapy administered.12,15,16 The
hypothesis of re-baseline of the reference MRI scan
after the time necessary for the drug to reach its full
effect was proposed previously.14,15
This difficulty in indicating a cutoff of MRI le-
sions that could be valid in all situations is again seen
in the present study, where the cutoff of 3 new T2 le-
sions emerged, which was different from the cutoffs
suggested in previous studies, ranging from 15 to 5.8
It is likely, for example, that differences in the MRI
lesion cutoffs found between this study and the one
we recently published on this topic8 could lie in the
causes of MRI variability described above. What
clearly emerges from the present analysis, however,
is that the combination of clinical relapses with sub-
stantial MRI activity appears as the best predictor of
short-term disease progression, whereas minimal
MRI activity alone is not. In particular, the present
analysis suggests that (1) over the first year of IFN-b
Figure 2 Expanded Disability Status Scale (EDSS worsening)–free survival
EDSS worsening–free survival over 3 years in the merged Magnetic Resonance Imaging in
MS dataset (1,280 patients) following the first year of therapy, according to combinations of
new T2 lesions and relapses during the first year of therapy groped in a 3-level score.
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therapy, a low level of MRI activity (i.e., 1–2 new T2
lesions) without clinical relapses produces a negligibly
low increase in the risk of clinical worsening in the
following 2–3 years (similar to the risk of those who
were MRI activity free, 21% vs 19%, p 5 0.58); (2)
over the same period of IFN-b treatment, an increase
in the risk of disease worsening is detectable when 1
relapse or substantial MRI activity (i.e., $3 new T2
lesions) occurs during the first year of IFN-b therapy
(risk of failure around 28%); (3) a high increase in the
risk of failure is present when, after 1 year of IFN-b
treatment, there is 1 relapse and substantial MRI
activity (i.e.,$3 new T2 lesions) or$2 relapses (risk
of failure around 48%). These findings can help clini-
cians evaluate short-term response to IFN-b and
therefore guide decisions on switching treatment in
patients treated with IFN-b as their first-line therapy
for MS.
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